AU741754B2 - 2-aminopyridines as inhibitors of cyclooxygenase-2 - Google Patents

2-aminopyridines as inhibitors of cyclooxygenase-2 Download PDF

Info

Publication number
AU741754B2
AU741754B2 AU90586/98A AU9058698A AU741754B2 AU 741754 B2 AU741754 B2 AU 741754B2 AU 90586/98 A AU90586/98 A AU 90586/98A AU 9058698 A AU9058698 A AU 9058698A AU 741754 B2 AU741754 B2 AU 741754B2
Authority
AU
Australia
Prior art keywords
phenyl
methylsulfonyl
group
compound according
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU90586/98A
Other versions
AU9058698A (en
Inventor
Denis Deschenes
Daniel Dube
Richard Friesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800689.3A external-priority patent/GB9800689D0/en
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Assigned to MERCK FROSST CANADA & CO. reassignment MERCK FROSST CANADA & CO. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK FROSST CANADA INC.
Publication of AU9058698A publication Critical patent/AU9058698A/en
Application granted granted Critical
Publication of AU741754B2 publication Critical patent/AU741754B2/en
Assigned to MERCK FROSST CANADA LTD. reassignment MERCK FROSST CANADA LTD. Alteration of Name(s) in Register under S187 Assignors: MERCK FROSST CANADA & CO.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).

Description

WO 99/14195 PCT/CA98/00861 TITLE OF THE INVENTION 2-AMINOPYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 BACKGROUND OF THE INVENTION This invention relates to methods of treating cyclooxygenase mediated diseases and certain pharmaceutical compositions therefor.
Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Initially, only one form of cyclooxygenase was known, this corresponding to cyclooxygenase-1 (COX-1) or the constitutive enzyme, as originally identified in bovine seminal vesicles.
More recently the gene for a second inducible form of cyclooxygenase, cyclooxygenase-2 (COX-2) has been cloned, sequenced and characterized initially from chicken, murine and human sources. This enzyme is distinct from the COX-1 which has been cloned, sequenced and characterized from various sources including the sheep, the mouse and man. The second form of cyclooxygenase, COX-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, we have concluded that the constitutive enzyme, COX-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, COX-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of COX-2 will have similar antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects. In particular, such a compound -1- WO 99/14195 PCTCA98/00861 should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.
Furthermore, such a compound will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, for decreasing bone loss particularly in postmenopausal women treatment of osteoporosis) and for the treatment of glaucoma.
The potential utilities of selective cyclooxygenase-2 inhibitors are discussed in the following articles: 1. John Vane, "Towards a better aspirin" in Nature, Vol. 367, pp. 215- 216, 1994 2. Bruno Battistini, Regina Botting and Y.S. Bakhle, COX-1- and COX-2: Toward the Development of More Selective NSAIDs" in Drug News and Perspectives, Vol. 7, pp. 501-512, 1994.
3. David B. Reitz and Karen Seibert, "Selective Cyclooxygenase Inhibitors" in Annual Reports in Medicinal Chemistry James A.
Bristol, Editor, Vol. 30, pp. 179-188, 1995.
4. Don E. Griswold and Jerry L. Adams, Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date" in Medicinal Research Reviews, Vol. 16, pp. 181-206, 1996.
WO 99/14195 PCT/CA98/00861 SUMMARY OF THE INVENTION The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I.
SO
2
R
1 R 2 N AR
I
The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
DETAILED DESCRIPTION OF THE INVENTION The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I, SO 2
R'
R
2
N
AR
-3- WO 99/14195 PTC9/06 PCT/CA98/00861 -AR is selected from the group consisting of (a) (d)
N
xD (b)
XN
(C)
(N
x (h)
N
or a pharmaceutically acceptable salt thereof wherein: WO 99/14195PC/A806 PCT/CA98/00861 X is selected from the group consisting of
CR
3
R
4 0,
S,
R1 is selected from the group consisting of CH3, NH2, NHC(0)CF3,
R
2 is chosen from the group consisting of hydrogen C1-6alkyl C1-6alkoxy, Cl-6alkylthio, Cl-6fluoroalkyl, Mf C1-6fluoroalkoxy,
CN,
-C02R 6 Wi -C(R 7
)(R
8
)-OH,
Wj -Cl-6alkyl-C02-R 9 halo, hydroxy,' (in) N3, (in) N02,
NR
1
OR
1 1
NHCOR
12
R
3 and R 4 are independently chosen from the group consisting of hydrogen, (CH2)pOR 5
F,
or R 3 and R 4 are together 0, WO 99/14195 PCT/CA98/00861
R
5 is selected from the group consisting of hydrogen, C1-6alkyl,
R
6 to R 1 2 are independently chosen from the group consisting of hydrogen C1-6alkyl, and p is0, 1,2.
One preferred embodiment of the invention is that wherein
R
1 is CH3.
Another preferred embodiment of the invention is that wherein R 2 is halo or C1-6fluoroalkyl.
Another preferred embodiment of the invention is that wherein X is CR 3
R
4 In another aspect, the invention also encompasses a pharmaceutical composition for treating an inflammatory disease susceptible to treatment with an non-steroidal anti-inflammatory agent comprising: a non-toxic therapeutically effective amount of a compound of formula I and a pharmaceutically acceptable carrier.
In another aspect the invention also encompasses a pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising: a non-toxic therapeutically effective amount of a compound of formula I and a pharmaceutically acceptable carrier.
In another aspect the invention also encompasses a method of treating an inflammatory disease susceptible to treatment with an non-steroidal anti-inflammatory agent comprising: -6- WO 99/14195 PCT/CA98/00861 administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of formula I and a pharmaceutically acceptable carrier.
In another aspect the invention also encompasses a method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of formula I.
In another aspect the invention also encompasses the use of a compound of formula I or a pharmaceutical composition in the manufacture of a medicament for the treatment of an inflammatory disease susceptible to treatment with an a non-steroidal antiinflammatory agent.
The invention is illustrated by the compounds of the Examples disclosed herein as well as the compounds of Table I.
1) Definitions The following abbreviations have the indicated meanings: AA arachidonic acid Ac acetyl AIBN 2.2--azobisisobutyronitrile Bn benzyl CHO chinese hamster ovary CMC 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimidemetho-p-toluenesulfonate COX cyclooxygenase DBU diazabicyclo[5.4.0]undec-7-ene DMAP 4-(dimethylamino)pyridine DMF N,N-dimethylformamide DMSO dimethyl sulfoxide Et3N triethylamine WO 99/14195 WO 9914195PCT/CA98/00861 HBSS =Hanks balanced salt solution HEPES [2-Hydlroxyethyl] piperazine-N 1 [2ethanesulfonic acid] HWB =human whole blood IPA =isopropyl alcohol KHMS =potassium hexamethyldisilazane LDA =lithium diisopropylamide LI'S =lipopolys acch aride inCPBA =metachioro perbenzoic acid MMPP =magnesium monoperoxyphthalate Ms =methanesulfonyl mesyl MsO methanesulfonate mesylate NBS =N-bromosuccinimide NCS =N-chlorosuccinimide NIS =N-iodosuccinimide NSAID =non-steroidal anti -infl amm atory drug ODCB =o-dichlorobenzene Oxone® potassium peroxymonosulfate PCC =pyridinium chliorochromate PDC =pyridinium dichromate r.t. =room temperature rac. =racemic Tf =trifluoromethanesulfonyl triflyl TFAA =trifluoroacetic anhydride Tfo= trifluoromethanesulfonate triflate THF =tetrahydrofuran TLC =thin layer chromatography TMPD =N,N,N',N'-tetramethyl-p-phenylenediamine WO 99/14195 PCT/CA98/00861 Ts TsO Tz SO2Me SO2NH2 p-toluenesulfonyl tosyl p-toluenesulfonate tosylate 1H (or methyl sulfone also SO2CH3) sulfonamide Alkvl group abbreviations Me Et n-Pr i-Pr n-Bu i-Bu s-Bu t-Bu c-Pr c-Bu c-Pen c-Hex methyl ethyl normal propyl isopropyl normal butyl isobutyl secondary butyl tertiary butyl cyclopropyl cyclobutyl cyclopentyl cyclohexyl Dose Abbreviations bid bis in die twice daily qid quater in die four times a day tid ter in die three times a day For purposes of this specification "Alkyl" means linear branched and cyclic structures, and combinations thereof, containing the indicated number of carbon atoms. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, eicosyl, 3,7-diethyl-2,2-dimethyl- 4-propylnonyl, cyclopropyl, cyclopentyl, cycloheptyl, adamantyl, cyclododecylmethyl, 2-ethyl-1bicyclo[4.4.0]decyl and the like.
For purposes of this specification "Fluoro alkyl" means alkyl groups, containing the indicated number of carbon atoms, in which one or more hydrogens is replaced by fluorine. Examples are CF3, -CH2CH2F, -CH2CF3, c-Pr-F5, c-Hex-F11 and the like.
For purposes of this specification "Alkoxy" means alkoxy groups of the indicated number of carbon atoms of a straight, branched, -9- WO 99/14195 PCT/CA98/00861 or cyclic configuration. Examples of alkoxy groups include meothoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like.
For purposes of this specification "Alkylthio" means alkylthio groups of the indicated number of carbon atoms of a straight, branched or cyclic configuration. Examples of alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH2GH2CH3.
For purposes of this specification "Fluoroalkoxy" means alkoxy groups of the indicated number of carbon atoms of a straight, branched, or cyclic configuration,in which one or more hydrogens is replaced by fluorine. Examples of fluoroalkoxy alkoxy groups include OCF3, -OCHF2, -OCH2CH2CH2F, and the like.
For purposes of this specification "halo" means F, Cl, Br, or I.
Exemplifying the invention are: 3-(4-Methylsulfonyl )phenyl-2-pyrrolidin- trif u oromethylpyri dine, 3-(4-Methylsulfonyl)phenyl-2-piperidin- trifl uorom ethylpyri dine, 5-Chloro-3-(4-methylsulfonyl )phenyl-2-piperidin- 1ylpyridine, 3-(4-Methylsulfonyl)phenyl-2-piperidin- 1-ylpyridine, .3-(4-Methylsulfonyl)phenyl-2-( 1,2,3 trifluoromethylpyridine, 2-(Homopiperidin-1-yl)-3-(4-methylsulfonyl)phenyl-5trifluoromethylpyridine, 3-(4-Methylsulfonyl)phenyl-2-((2S)-2hydroxymethyl)pyrrolidin- 3-(4-Methylsulfonyl)phenyl-2-((2R)-2hydroxyinethyl)pyrrolidin- 5-Chloro-3-(4-methylsulfonyl)phenyl-2-((2S)-2hydroxymethyl)pyrrolidin- 1-ylpyridine, 3-(4-Methylsulfonyl)phenyl-2-((2S)-2methoxymethyl)pyrrolidin- WO 99/1 4195 PTC9/06 PCT/CA98/00861 (11) 3-(4-Methylsulfonyl)phenyl-2-((2S)-2acetoxyxnethyl)pyrrolidlin- (12) 5-Chloro-3-(4-methylsulfonyl)phenyl-2-((2S)-2methoxymethyl)pyrrolidin- 1-ylpyridine, (13) 3-(4-Methylsulfonyl)phenyl-2-(2-hydroxynaethyl)piperi din-i1- (14) (-)-3-(4-Methylsulfonyl)phenyl-2-(3hydroxymethyl)piperidin- (+)-3-(4-Methylsulfonyl)phenyl-2-(3hydroxymethyl)piperidin- (16) 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3hydroxyniethyl)piperidin- 1-ylpyridine, (17) 3-(4-Methylsulfonyl)phenylb2-(3-hydroxymethyl-3methyl )piperidin- (18) 3-(4-Methylsulfonyl)phenyl-2-(3hydroxymethyl)homopiperidin- (19) 3-(4-Methylsulfonyl)phenyl-2-(2-(2-hydroxyethyl))piperidin- 3-(4-Methylsulfonyl)phenyl-2-(4-oxo)piperidin- trifluoromethylpyridine, (21) 3-(4-Methylsulfonyl)phenyl-2-(3-oxo)piperidin- i-yl- 5 trifluorom ethylpyri dine, (22) 3-(4-Methylsulfonyl)phenyl-2-(4-hydroxy)piperidin- trifluorom ethylpyri dine, (23) 3-(4-Methylsulfonyl)phenyl-2-(3-hydroxy)piperidin- trifluoromethylpyridine, (24) 2-(4,4-Difluoro)piperidin- 1-yl-3-(4-methylsulfonyl)phenyl-5trifluoromethylpyridine, 2-(3 ,3-Difluoro)piperidin-1-yl-3-(4-methylsulfonyl)phenyl-5trifluoromethylpyridine, (26) 2-(4-Fluoro)piperidin- 1-yI-3-(4-methylsulfonyl)phenyl-5trifluoromethylpyridine, (27) 3-(4-Methylsulfonyl)phenyl-2-morpholin-4-yl-5trifluoromethylpyridine, 11 WO 99/14195 PCT/CA98/00861 (28) 3-(4-Methylsulfonyl)phenyl-2-thiomorpholin-4-yl-5trifluoromethylpyridine, Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.
Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
In a second embodiment, the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase and for treating cyclooxygenase mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of formula I as described above.
Within this embodiment the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase-2 and for treating cyclooxygenase-2 mediated diseases as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of formula I as described above.
In a third embodiment, the invention encompasses a method of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases, advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 as disclosed herein comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I as disclosed herein.
The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a -12- WO 99/14195 PCT/CA98/00861 pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N,Ndibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2dimethylaminoethanol, ethanolamine, ethylenediamine, Nethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like, and basic ion exchange resins.
It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.
The compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer.
Compound I may also be of use in the treatment and/or prevention of cyclooxygenase-mediated proliferative disorders such as may occur in diabetic retinopathy and tumor angiogenesis.
-13- WO 99/14195 PCT/CA98/00861 Compound I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, and for the prevention of bone loss (treatment of osteoporosis) and for the treatment of glaucoma.
By virtue of its high cyclooxygenase-2 (COX-2) activity and/or its specificity for cyclooxygenase-2 over cyclooxygenase-1 (COX-1), Compound I will prove useful as an alternative to conventional nonsteroidal antiinflammatory drugs (NSAID'S) particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; those prior to surgery or taking anticoagulants.
Similarly, Compound I, will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or ingredients.
Thus in further aspects, the invention encompasses pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetominophen or phenacetin; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levodesoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a prostaglandin including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; a diuretic; a sedating or non-sedating antihistamine. In addition the invention encompasses a method of treating cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound -14- WO 99/14195 PCT/CA98/0086 1 of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.
For the treatment of any of these cyclooxygenase mediated diseases Compound I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warmblooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.
As indicated above, pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined may optionally include one or more ingredients as listed above.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl WO 99/14195 PCT/CA98/00861 monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or npropyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral -16- WO 99/14195 PCT/CA98/0086 I preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxy-ethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension.
This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- -17- WO 99/14195 PCT/CA98/00861 or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Compound I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of Formula I are employed.
(For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the aboveindicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, -18- WO 99/14195 PCT/CA98/00861 route of administration, rate of excretion, drug combination ahd the severity of the particular disease undergoing therapy.
Methods of Synthesis The compounds of Formula I of the present invention can be prepared according to the synthetic routes outlined in Scheme 1 and by following the methods described therein.
Scheme 1 The 2 -aminopyridines of Formula I may be prepared in a multi-step sequence from the requisite 2-aminopyridine II. Initial bromination of II with bromine in acetic acid provides the bromide III.
A palladium-catalyzed coupling of III with 4-(methylthio)phenylboronic acid in the presence of a suitable base, such as sodium carbonate, provides the sulfide IV which can be oxidized using one of several oxidants, such as MMPP, oxone®, or OsO4/NMO to the corresponding sulfone V. The amino pyridine V can be converted to the 2-halopyridine VI (X Br, Cl) by treatment of V with sodium nitrite and either HBr/Br2 or HC1 followed by reaction with POCl3. Treatment of VI with an appropriately substituted amine VII and a suitable base such as K2CO3, Cs2CO3 or KH in an inert solvent such as DMF or DMSO, or alternatively heating a neat mixture of the amine VII and VI in the presence of a copper salt such as Cul, provides the 2-aminopyridine of Formula I.
19 SUBSTITUTE SHEET (RULE 26) WO 99/14195 WO 9914195PCT/CA98/00861 Scheme 1 SMe Br 2 HOAc P. Br (HO) 2 B RZ~ N NH 2
N'NH
2 Pd catalyst
NH
2 oxidant
,SO
2 Me
NH
2 VI (Y Br, CI) Ibase H-Ar Representative Compounds Tables I illustrates novel compounds of the present invention.
20 SUBSTITUT2 SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 TABLE I S0 2
R'
Example Stereochemistry M e CF3 Me CF3 Me Cl Me H
N
L:>
4 Me CF3 Me CF3 21 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/O 0861 Me CF3 M e CF3 TABLE I (CONTINUED)
HO,,O
HO' O.D 11 12 13 Me Cl Me CF3 Me CF3 Me Cl Me CF3 \1N 11N MeO.D
N
AcO..Y
"N
MeO, HO1 (s) (s) (s) (s) rac emi c Z-1
OH
Me CF3 22 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/0086 I TABLE I (CONTETUED)
OH
16 17 Me CF 3 Me Cl M e CF3 ra ceni c ra cemi c
HOP
Me CF3 Me CF3 rac eni c
HO"
23racemi c SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/0086 I TABLE I (CONTINUED) 'Na 0 M e CF3 0 Me CF3 OH Me CF3 0OH Me CF3 rac emi c 24 Me CF3 M e CF3 Me CF3
F
F
"-'NF
F F "NaF 24 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 TABLE I (CONTINUED) 27 Me CF3
-N
28 Me CF3
S
Assays for determining Biological Activity The compound of Formula I can be tested using the following assays to determine their cyclooxygenase-2 inhibiting activity.
INHIBITION OF CYCLOOXYGENASE
ACTIVITY
Whole cell assays for COX-2 and COX-1 using CHO transfected cell lines Chinese hamster ovary (CHO) cell lines which have been stably transfected with an eukaryotic expression vector pCDNAIII containing either the human COX-1 or COX-2 cDNA's are used for the assay. These cell lines are referred to as CHO [hCOX-1] and CHO [hCOX-2], respectively. For cyclooxygenase assays, CHO[hCOX-1] cells from suspension cultures and CHO[hCOX-2] cells prepared by trypsinization of adherent cultures are harvested by centrifugation (300 x g, 10 min) and washed once in HBSS containing 15 mM HEPES, pH 7.4, and resuspended in HBSS, 15 mM HEPES, pH 7.4, at a cell concentration of 1.5 x 106 cells/ml. Drugs to be tested are dissolved in DMSO to 66.7-fold the highest test drug concentration. Compounds are typically tested at 8 concentrations in duplicate using serial 3-fold serial dilutions in DMSO of the highest drug concentration. 'Cells (0.3 x 106 cells in 200 pl) are preincubated with 3 4 of the test drug or DMSO vehicle for 15 min at 37C. Working solutions of peroxide-free AA (5.5 pM and 110 pM AA for the CHO [hCOX-1] and CHO [COX-2] assays, respectively) are prepared by a 10-fold dilution of a concentrated AA solution in ethanol into HBSS 25 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 containing 15 mM HEPES, pH 7.4. Cells are then challenged in the presence or absence of drug with the AA/HBSS solution to yield a final concentration of 0.5 pM AA in the CHO[hCOX-1] assay and a final concentration of 10 1M AA in the CHO[hCOX-2] assay. The reaction is terminated by the addition of 10 pl 1 N HC1 followed by neutralization with 20 pl of 0.5 N NaOH. The samples are centrifuged at 300 x g at 4'C for 10 min, and an aliquot of the clarified supernatant is appropriately diluted for the determination of PGE2 levels using an enzyme-linked immunoassay for PGE2 (Correlate PGE2 enzyme immunoassay kit, Assay Designs, Inc.). Cyclooxygenase activity in the absence of test compounds is determined as the difference in PGE2 levels of cells challenged with arachidonic acid versus the PGE2 levels in cells mockchallenged with ethanol vehicle. Inhibition of PGE2 synthesis by test compounds is calculated as a percentage of the activity in the presence of drug versus the activity in the positive control samples.
Assay of COX-1 Activity from U937 cell microsomes U 937 cells are pelleted by centrifugation at 500 x g for 5 min and washed once with phosphate-buffered saline and repelleted. Cells are resuspended in homogenization buffer consisting of 0.1 M Tris-HC1, pH 7.4, 10 mM EDTA, 2 gg/ml leupeptin, 2 gg/ml soybean trypsin inhibitor, 2 gg/ml aprotinin and 1 mM phenyl methyl sulfonyl fluoride.
The cell suspension is sonicated 4 times for 10 sec and is centrifuged at 10,000 x g for 10 min at 4° C. The supernatant is centrifuged at 100,000 x g for 1 hr at 4 C. The 100,000 x g microsomal pellet is resuspended in 0.1 M Tris-HC1, pH 7.4, 10 mM EDTA to approximately 7 mg protein/ml and stored at -80" C.
Microsomal preparations are thawed immediately prior to use, subjected to a brief sonication, and then diluted to a protein concentration of 125 gg/ml in 0.1 M Tris-HCl buffer, pH 7.4 containing mM EDTA, 0.5 mM phenol, 1 mM reduced glutathione and 1 pM hematin. Assays are performed in duplicate in a final volume of 250 .1.
Initially, 5 p1 of DMSO vehicle or drug in DMSO are added to 20 pl of 0.1 M Tris-HCl buffer, pH 7.4 containing 10 mM EDTA in wells of a 96- 26 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 deepwell polypropylene titre plate. 200 pl of the microsomal preparation are then added and pre-incubated for 15 min at room temperature before addition of 25 pl of 1 M arachidonic acid in 0.1 M Tris-HCl and 10 mM EDTA, pH 7.4. Samples are incubated for 40 min at room temperature and the reaction is stopped by the addition of 25 p of 1 N HC1. Samples are neutralized with 25 pl of 1 N NaOH prior to quantitation of PGE2 content by radioimmunoassay (Dupont-NEN or Amersham assay kits).
Cyclooxygenase activity is defined as the difference between PGE2 levels in samples incubated in the presence of arachidonic acid and ethanol vehicle.
Assay of the activity of purified human COX-2 The enzyme activity is measured using a chromogenic assay based on the oxidation of N,N,N',N'-tetramethyl-pphenylenediamine (TMPD) during the reduction of PGG2 to PGH2 by COX-2 (Copeland et al. (1994) Proc. Natl. Acad. Sci. 91, 11202-11206).
Recombinant human COX-2 is purified from Sf9 cells as previously described (Percival et al (1994) Arch. Biochem. Biophys. 111-118). The assay mixture (180 contains 100 mM sodium phosphate, pH 6.5, 2 mM genapol X-100, 1 p.M hematin, 1 mg/ml gelatin ,80-100 units of purified enzyme (One unit of enzyme is defined as the amount of enzyme required to produce an O.D. change of 0.001/min at 610 nm) and 4 pL of the test compound in DMSO. The mixture is preincubated at room temperature (22°C) for 15 minutes prior to initiation of the enzymatic reaction by the addition of 20 pL of a sonicated solution of 1 mM arachidonic acid (AA) and 1 mM TMPD in assay buffer (without enzyme or hematin). The enzymatic activity is measured by estimation of the initial velocity of TMPD oxidation over the first 36 sec of the reaction. A non-specific rate of oxidation is observed in the absence of enzyme (0.007 0.010 O.D. /min) and is subtracted before the calculation of the inhibition. IC50 values are derived from 4-parameter least squares non-linear regression analysis of the log-dose vs inhibition plot.
HUMAN WHOLE BLOOD ASSAY 27 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 Rationale Human whole blood provides a protein and cell-rich milieu appropriate for the study of biochemical efficacy of anti-inflammatory compounds such as selective COX-2 inhibitors. Studies have shown that normal human blood does not contain the COX-2 enzyme. This is consistent with the observation that COX-2 inhibitors have no effect on PGE2 production in normal blood. These inhibitors are active only after incubation of human whole blood with LPS, which induces COX-2. This assay can be used to evaluate the inhibitory effect of selective COX-2 inhibitors on PGE2 production. As well, platelets in whole blood contain a large amount of the COX-1 enzyme. Immediately following blood clotting, platelets are activated through a thrombin-mediated mechanism. This reaction results in the production of thromboxane B2 (TxB2) via activation of COX-1. Thus, the effect of test compounds on TxB2 levels following blood clotting can be examined and used as an index for COX-1 activity. Therefore, the degree of selectivity by the test compound can be determined by measuring the levels of PGE2 after LPS induction (COX-2) and TxB2 following blood clotting (COX-1) in the same assay.
Method A. COX-2 (LPS-induced PGE2 production) Fresh blood is collected in heparinized tubes by venipuncture from both male and female volunteers. The subjects have no apparent inflammatory conditions and have not taken any NSAIDs for at least 7 days prior to blood collection. Plasma is immediately obtained from a 2mL blood aliquot to use as blank (basal levels of PGE2).
The remaining blood is incubated with LPS (100 gg/ml final concentration, Sigma Chem, #L-2630 from E. coli; diluted in 0.1% BSA (Phosphate buffered saline) for 5 minutes at room temperature. Five hundred gL aliquots of blood are incubated with either 2pL of vehicle (DMSO) or 2pL of a test compound at final concentrations varying from to 30jpM for 24 hours at 370C. At the end of the incubation, the blood is centrifuged at 12,000 x g for 5 minutes to obtain plasma. A 100L 28 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 aliquot of plasma is mixed with 400pL of methanol for proteinprecipitation. The supernatant is obtained and is assayed for PGE2 using a radioimmunoassay kit (Amersham, RPA#530) after conversion of PGE2 to its methyl oximate derivative according to the manufacturer's procedure.
B. COX-1 (Clotting-induced TxB 2 production) Fresh blood is collected into vacutainers containing no anticoagulants. Aliquots of 500p.L are immediately transferred to siliconized microcentrifuge tubes preloaded with 2piL of either DMSO or a test compound at final concentrations varying from 10nM to The tubes are vortexed and incubated at 37 0 C for 1 hour to allow blood to clot. At the end of incubation, serum is obtained by centrifugation (12,000 x g for 5 min.). A 100gpL aliquot of serum is mixed with 400p.L of methanol for protein precipitation. The supernatant is obtained and is assayed for TxB2 using a enzyme immunoassay kit (Cayman, #519031) according to the manufacturer's instruction.
RAT PAW EDEMA ASSAY Protocol Male Sprague-Dawley rats (150-200 g) are fasted overnight and are given, po, either vehicle methocel or 5% Tween 80) or a test compound. One hr later, a line is drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (VO) is measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water displacement. The animals are then injected subplantarly with 50 ml of 1% carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 2 5-gauge needle 500 mg carrageenan per paw). Three hr later, the paw volume (V3) is measured and the increases in paw volume (V3 VO) are calculated.
The animals are sacrificed by C02 asphyxiation and the absence or presence of stomach lesions scored. Data is compared with the vehicle- 29 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 control values and percent inhibition calculated. All treatment groups are coded to eliminate observer bias.
LPS-Induced Pvrexia in Conscious Rats Male Sprague-Dawley rats (150 200 g) were fasted for 16 18 h before use. At approximately 9:30 the animals were placed temporarily in plexiglass restrainers and their baseline rectal temperature was recorded using a flexible temperature probe (YSI series 400) connected to a digital thermometer (Model 08502, Cole Parmer). The same probe and thermometer were used for all animals to reduce experimental error. The animals were returned to their cages after the temperature measurements. At time zero, the rats were injected intraperitoneally with either saline or LPS (2 mg/kg, Sigma Chem) and the rectal temperature was remeasured at 5, 6 and 7 h following LPS injection. After the measurement at 5 h, when the increase in temperature had reached a plateau, the LPS-injected rats were given either the vehicle methocel) or a test compound orally to determine whether the compound could reverse the pyrexia. Percent reversal of the pyrexia was calculated using the rectal temperature obtained at 7 h in the control (vehicle-treated) group as the reference (zero reversal) point. Complete reversal of pyrexia to the pre-LPS baseline value is taken as 100%.
LPS-Induced Pvrexia in Conscious Squirrel Monkeys Temperature probes were surgically implanted under the abdominal skin in a group of squirrel monkeys (Saimiri sciureus) (1.0 1.7 kg). This allows for the monitoring of body temperature in conscious, unrestrained monkeys by a telemetric sensing system (Data Sciences International, Minnesota). The animals were fasted and were placed in individual cages for acclimatization 13 14 h before use. Electronic receivers were installed on the side of the cages which pick up signals from the implanted temperature probes. At approximately 9:00 a.m. on the day of the experiment, the monkeys were restrained temporarily in training chairs and were given a bolus I.V. injection of LPS, (6 30 SUBSTITUTE SHEET (RULE 26)
J.
WO 99/14195 PCT/CA98/00861 mg/kg, dissolved in sterile saline). The animals were returned to their cages and body temperature was recorded continuously every 5 min.
Two h after injection of LPS, when the body temperature had increased by 1.5 2oC, the monkeys were dosed orally with either vehicle (1% methocel) or a test compound (3 mg/kg). One hundred minutes later, the difference between the body temperature and the baseline value was determined. Percent inhibition was calculated taking the value in the control group as 0% inhibition.
Acute Inflammatory Hvperalgesia Induced by Carrageenan in Rats Experiments were performed using male Sprague Dawley rats 9 0 -110g). Hyperalgesia to mechanical compression of the hind paw was induced by intraplantar injection of carrageenan (4.5 mg into one hind paw) 3 h previously. Control animals received an equivalent volume of saline (0.15 ml intraplantar). A test compound (0.3-30 mg/kg, suspended in 0.5% methocel in distilled water) or vehicle methocel) was administered orally (2ml/kg) 2 h after carrageenan. The vocalisation response to compression of the hind paw was measured 1 h later using a Ugo Basile algesiometer.
Statistical analysis for carrageenan-induced hyperalgesia was performed using one-way ANOVA (BMDP Statistical Software Inc.). Hyperalgesia was determined by subtracting the vocalisation threshold in saline injected rats from that obtained in animals injected with carrageenan. Hyperalgesia scores for drug-treated rats were expressed as a percentage of this response. ID 5 0 values (the dose producing 50% of the maximum observed response) were then calculated by nonlinear least squares regression analysis of mean data using GraFit (Erithacus Software).
Adiuvant-Induced Arthritis in Rats Seventy, 6.5-7.5 week old, female Lewis rats (body weight -146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which arthritis was not induced, a vehicle 31 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of Mycobacterium butyricum in 0.1 ml of light mineral oil (adjuvant), and a negative control group of rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day and 21 days following adjuvant injection, and primary paw volumes were determined before (day and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 0.1 ml of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume narrowing or widening of joint spaces subchondral erosion periosteal reaction osteolysis (0-4) subluxation and degenerative joint changes Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, Indomethacin at a total daily dose of 1 mg/kg/day, or vehicle methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds were prepared weekly, refrigerated in the dark until used, and vortex mixed immediately prior to administration.
Two-factor ('treatment' and 'time') analysis of variance with repeated measures on 'time' were applied to the changes for body weight and foot volumes and to the rank-transformed radiographic total scores. A post hoc Dunnett's test was conducted to compare the effect of 32 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 treatments to vehicle. A one-way analysis of variance was applied to the thymic and spleen weights followed by the Dunnett's test to compare the effect of treatments to vehicle. Dose-response curves for inhibition in foot volumes on days 4, 14 and 21 were fitted by a 4-parameter logistic function using a nonlinear least squares' regression. ID 5 0 was defined as the dose corresponding to a 50% reduction from the vehicle and was derived by interpolation from the fitted 4-parameter equation.
PHARMACOKINETICS IN RATS Per Os Pharmacokinetics in Rats
PROCEDURE:
The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.
Male Sprague Dawley rats (325-375 g) are fasted overnight prior to each PO blood level study.
The rats are placed in the restrainer one at a time and the box firmly secured. The zero blood sample is obtained by nicking a small (1 mm or less) piece off the tip of the tail. The tail is then stroked with a firm but gentle motion from the top to the bottom to milk out the blood. Approximately 1 mL of blood is collected into a heparinized vacutainer tube.
Compounds are prepared as required, in a standard dosing volume of and administered orally by passing a 16 gauge, 3" gavaging needle into the stomach.
Subsequent bleeds are taken in the same manner as the zero bleed except that there is no need to nick the tail again. The tail is cleaned with a piece of gauze and milked/stroked as described above into the appropriately labelled tubes.
Immediately after sampling, blood is centrifuged, separated, put into clearly marked vials and stored in a freezer until analysed.
33 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 Typical time points for determination of rat blood levels after PO dosing are: 0, 15min, 30min, lh, 2h, 4h, 6h After the 4 hr time point bleed, food is provided to the rats ad libitum.
Water is provided at all times during the study.
Vehicles: The following vehicles may be used in PO rat blood level determinations: PEG 200/300/400: restricted to 2 mL/kg Methocel 0.5% Tween 80: Compounds for PO blood levels can be in suspension form. For better dissolution, the solution can be placed in a sonicator for approximately minutes.
For analysis, aliquots are diluted with an equal volume of acetonitrile and centrifuged to remove protein precipitate. The supernatant is injected directly onto a C-18 HPLC column with UV detection.
Quantitation is done relative to a clean blood sample spiked with a known quantity of drug. Bioavailability is assessed by comparing area under the curve (AUC) i.v. versus p.o.
F AUCpo x DOSEiv x 100% AUCiv DOSEpo Clearance rates are calculated from the following relation: CL DOSEiv(mg/kg) AUCiv The units of CL are mL/h.kg (milliliters per hour kilogram) Intravenous Pharmacokinetics in Rats 34 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861
PROCEDURE:
The animals are housed, fed and cared for according to the Guidelines of the Canadian Council on Animal Care.
Male Sprague Dawley (325-375 g) rats are placed in plastic shoe box cages with a suspended floor, cage top, water bottle and food.
The compound is prepared as required, in a standard dosing volume of 1 mL/kg.
Rats are bled for the zero blood sample and dosed under C02 sedation.
The rats, one at a time, are placed in a primed C02 chamber and taken out as soon as they have lost their righting reflex. The rat is then placed on a restraining board, a nose cone with C02 delivery is placed over the muzzle and the rat restrained to the board with elastics. With the use of forceps and scissors, the jugular vein is exposed and the zero sample taken, followed by a measured dose of compound which is injected into the jugular vein. Light digital pressure is applied to the injection site, and the nose cone is removed. The time is noted. This constitutes the zero time point.
The 5 min bleed is taken by nicking a piece (1-2 mm) off the tip of the tail.
The tail is then stroked with a firm but gentle motion from the top of the tail to the bottom to milk the blood out of the tail. Approximately 1 mL of blood is collected into a heparinized collection vial. Subsequent bleeds are taken in the same fashion, except that there is no need to nick the tail again. The tail is cleaned with a piece of gauze and bled, as described above, into the appropriate labelled tubes.
Typical time points for determination of rat blood levels after I.V. dosing are either: 0, 5 min, 15min, 30min, lh, 2h, 6h or 0, 5 min, 30min, lh, 2h, 4h, 6h.
35 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 Vehicles: The following vehicles may be used in IV rat blood level determinations: Dextrose: lmL/kg Moleculosol 25%: ImL/kg DMSO (dimethylsulfoxide): Restricted to a dose volume of 0.1 mL per animal PEG 200: Not more than 60% mixed with 40% sterile water lmlJkg With Dextrose, either sodium bicarbonate or sodium carbonate can be added if the solution is cloudy.
For analysis, aliquots are diluted with an equal volume of acetonitrile and centrifuged to remove protein precipitate. The supernatant is injected directly onto a C-18 HPLC column with UV detection.
Quantitation is done relative to a clean blood sample spiked with a known quantity of drug. Bioavailability is assessed by comparing area under the curve (AUC) i.v. versus p.o.
F AUCpo x DOSEiv x 100% AUCiv DOSEpo Clearance rates are calculated from the following relation: CL DOSEiv(mg/kg) AUCiv The units of CL are mL/Jhkg (milliliters per hour kilogram) NSAID-INDUCED GASTROPATHY IN RATS Rationale The major side effect of conventional NSAIDs is their ability to produce gastric lesions in man. This action is believed to be caused by inhibition of Cox-1 in the gastrointestinal tract. Rats are particularly 36 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 sensitive to the actions of NSAIDs. In fact, rat models have been used commonly in the past to evaluate the gastrointestinal side effects of current conventional NSAIDs. In the present assay, NSAID-induced gastrointestinal damage is observed by measuring fecal 5 1 Cr excretion after systemic injection of 5 1 Cr-labeled red blood cells. Fecal 5 1 Cr excretion is a well-established and sensitive technique to detect gastrointestinal integrity in animals and man.
Methods Male Sprague Dawley rats (150 200 g) are administered orally a test compound either once (acute dosing) or b.i.d. for 5 days (chronic dosing). Immediately after the administration of the last dose, the rats are injected via a tail vein with 0.5 mL of 5 1 Cr-labeled red blood cells from a donor rat. The animals are placed individually in metabolism cages with food and water ad lib. Feces are collected for a 48 h period and 5 1 Cr fecal excretion is calculated as a percent of total injected dose. 5 1 Cr-labeled red blood cells are prepared using the following procedures. Ten mL of blood is collected in heparinized tubes via the vena cava from a donor rat. Plasma is removed by centrifugation and replenished with equal volume of HBSS. The red blood cells are incubated with 400 Ci of sodium 5 1 chromate for 30 min. at 37C. At the end of the incubation, the red blood cells are washed twice with 20 mL HBSS to remove free sodium 5 1 chromate. The red blood cells are finally reconstituted in 10 mL HBSS and 0.5 mL of the solution (about 20 Ci) is injected per rat.
PROTEIN-LOSING GASTROPATHY IN SQUIRREL MONKEYS Rationale Protein-losing gastropathy (manifested as appearance of circulating cells and plasma proteins in the GI tract) is a significant and dose-limiting adverse response to standard non-steroidal antiinflammatory drugs (NSAIDs). This can be quantitatively assessed by intravenous administration of 5 1 CrC13 solution. This isotopic ion can avidly bind to cell and serum globins and cell endoplasmic reticulum.
37 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 Measurement of radioactivity appearing in feces collected for 24 h after administration of the isotope thus provides a sensitive and quantitative index of protein-losing gastropathy.
Methods Groups of male squirrel monkeys (0.8 to 1.4 kg) are treated by gavage with either 1% methocel or 5% Tween 80 in H20 vehicles, (3mL/kg or test compounds at doses from 1 100 mg/kg b.i.d. for days. Intravenous 5 1 Cr (5Ci/kg in 1 ml/kg phosphate buffer saline (PBS)) is administered 1 h after the last drug/vehicle dose, and feces collected for 24 h in a metabolism cage and assessed for excreted 5 1 Cr by gamma-counting. Venous blood is sampled 1 h and 8 h after the last drug dose, and plasma concentrations of drug measured by RP-HPLC.
Representative Biological Data Compounds of the present invention are inhibitors of cyclooxygenase-2 and are thereby useful in the treatment of cyclooxygenase-2 mediated diseases as enumerated above. The activities of the compounds against cyclooxygenase may be seen in the representative results shown below. In the assay, inhibition is determined by measuring the amount of prostaglandin E2 (PGE2) synthesized in the presence of arachidonic acid, cyclooxygenase-1 or cyclooxygenase-2 and a putative inhibitor. The IC50 values represent the concentration of putative inhibitor required to return PGE2 synthesis to of that obtained as compared to the uninhibited control.
The results for certain of the biological assays may be seen in Table II.
38 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/0086
I
TABLE II Examnple COX-2 (IC50 MM) CHO HWB cox-1 (1C50 MM) TT-937 HVYrB 1 2 3 4 5 6 7 8 9 10 U1 12 13 14 15 16 17 18 19 20 21 23 24 25 27 28 0.02 0.004 0.002 0.13 0.002 0.004 0.04 >5 0.03 0.09 0.07 0.01 0.10 0.03 0.03 0.24 0.40 0.08 0.92 0.09 0.11 0.03 0.03 0.02 0.08 0.01 0.06 0.03 9.7 0.3 0.2 6.0 1.0 6.0 0.2 >33 0.1 3.1 <0.4 5.3 2.7 0.5 26.6 0.7 5.3 23.4 3.2 10.4 5.3 10.8 7.5 10.3 4.7 1.7 3.6 1.4 3 1-3 1-3 3-10 1-3 3-10 3-10 3-10 3-10 3-10 >100 39 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise: all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; (ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm'Hg) with a bath temperature of up to (iii) the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; (iv) melting points are uncorrected and indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; (vi) yields are given for illustration only; (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal; (viii) chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)), r.t.(room temperature), h (hour(s)), min (minute(s)).
40 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 EXAMPLE 1 3-(4-Methvlsulfonvl)phenvl-2-prrolidin- Step 1: 2 -Amino-3-bromo-5-trifluoromethvlpvri dine To a solution of 2 -amino-5-trifluoromethylpyridine (9 g) in acetic acid (75 mL) at r.t. was added bromine (5.8 mL) slowly. After 1 h, the acid was neutralized by the careful addition of sodium hydroxide N) at 0°C. The resulting orange precipitate was dissolved in ether and washed successively with saturated potassium carbonate, saturated Na2SO3 and brine, dried and concentrated. The residual solid was stirred vigorously in hexane for 1 h to provide, after filtration, the title compound as a white solid (10.2 g).
Step 2: 2 -Amino- 3 A mixture of the bromide from Step 1, 4-methylthiobenzene boronic acid (Li, et. al. J. Med. Chem. 1995, 38, 4570) (8.5 2M aqueous sodium carbonate (60 mL) and palladium tetrakis(triphenylphosphine) (490 mg) in ethanol/benzene (100 mL, 1:1) was heated at reflux for 15 h.
The mixture was cooled to diluted with water and extracted with ether. The organics were concentrated and the residue was subjected to stirred vigorously in ether/hexane for 1 h to provide, after filtration, the title compound (11.2 g) as a beige solid.
Step 3: 2 -Amino- 3 4 pvridine A mixture of 2 -amino-3-(4-methylthio)phenyl-5-trifluoromethylpyridine (9.7 Os4 (2 mL of a 4% solution in water) and NMO (13 g) in acetone/water (60 mL:5 mL) was stirred at r.t. overnight.
Saturated aqueous Na2SO3 was then added and the resulting mixture was stirred for 30 min. The acetone was evaporated and the resulting mixture was extracted with ether and ethyl acetate. The combined organics were washed with Na2SO 3 water, brine and then concentrated. The solid residue was stirred vigorously in hexane and 41 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 ether for 1 h and then filtered to provide the title compound as a pale yellow solid (9.9 g).
Step 4: 2-Bromo-3-( 4 pvridine To a solution of 2 -amino-3-(4-methylsulfonyl)phenyl-5trifluoromethylpyridine (7.2 g) in 48% HBr (25 mL) and bromine (3.5 mL) at 0°C was carefully and slowly added sodium nitrite (3.9 The mixture was warmed to r.t. and stirred for 4 h. The mixture was treated with saturated sodium carbonate and extracted with ether. The organics were washed successively with saturated sodium bisulfite and brine, dried and concentrated. Flash chromatography (7:3 hexane/ethyl acetate) of the residue provided the title compound as a pale yellow solid (6.4 g).
Step 5: 3-(4-Methvlsulfonvl)phenvl-2-pvrrolidin- trifluorom ethylpvridine A mixture of pyrrolidine (0.5 mL), potassium carbonate (250 mg) and 2 -bromo-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine (150 mg) in DMSO (5 mL) was stirred at 65C until tic analysis indicated completion of the reaction (15 To the mixture was added 1 N HC1 and the mixture was extracted with ethyl acetate. The organics were washed with saturated sodium bicarbonate and brine, dried (MgSO4) and concentrated. Flash chromatography (1:1 hexane/ethyl acetate) or stirring the residual material vigorously in a suitable solvent (such as ether or ethyl acetate) provided the title compound as a white solid (93 mg), m.p. 184-187oC.
42 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 EXAMPLE 2 3-(4-Methvlsulfonvl)phenvl-2-piperidin- Following the procedures described in Example 1, Step but substituting piperidine for pyrrolidine, the title compound was obtained as a pale yellow solid, m.p. 159-160 0
C.
EXAMPLE 3 5-Chloro-3-(4-methylsulfonyl)phenvl-2-Diperidin-l-vlpvridine Step 1: 2 To a solution of 2 -amino-5-chloropyridine (10 g) in acetic acid (75 mL) at r.t. was added bromine (2.6 mL) slowly. After 30 min, the acid was neutralized by the careful addition of sodium hydroxide (10 N) at 0 C. The resulting orange precipitate was dissolved in ethyl acetate and washed successively with saturated potassium carbonate, saturated Na2S203 and brine, dried and concentrated. Flash chromatography (eluting with hexane/ethyl acetate, 3:1 v/v) of the residual solid provided the title compound as a pale yellow solid (14.8 g).
Step 2: 2 -Amino-5-chloro-3-(4-methvlsulfonvl)phenvlpyridine Following the procedures described in Example 1, Steps 2 and 3, but substituting 2 -amino-3-bromo-5-chloropyridine from Step 1 g) for 2 -amino-3-bromo-5-trifluoromethylpyridine, the title compound was obtained as a white solid (5.3 g).
Step 3: 2.5-Dichloro- 3 -(4-methylsulfonvl)phenvlpvridine To a solution of 2 -amino-5-chloro-3-(4methylsulfonyl)phenylpyridine (1.5 g) in dioxane/water (15 mL) and concentrated HCI (1.5 mL) at 0°C was added a solution of sodium nitrite (580 mg) in 1.5 mL water. The mixture was stirred at 5°C for 1 h and then 10 N NaOH was added until the pH was basic. The mixture was diluted with water and extracted four times with ether. The combined organics were washed with 10% NaOH, dried and concentrated. The 43 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 crude solid (1.4 g) and POC13 (3 L) was heated at 110 0 C for 3 h in a steel bomb. The mixture was cooled to diluted carefully with water and neutralized with 10 N NaOH. The mixture was extracted with ether and the organics were washed with brine, dried and concentrated. The solid material was recrystallized from toluene to provide the title compound as an off-white solid (1.2 g).
Step 4: 5-Chloro-3-(4-methylsulfonvl)Dhenvl-2-piDeridin- 1 vlpyridine A mixture of piperidine (250 mg), cesium carbonate (680 mg) and 2,5-dichloro-3-(4-methylsuifonyl)phenylpyridine (240 mg) in DMSO (3 mL) was stirred at 120 0 C until tlc analysis indicated completion of the reaction (15 To the mixture was added water and the mixture was extracted with ethyl acetate. The organics were washed with brine, dried (MgS04) and concentrated. Chromatography (1:1 hexane/ethyl acetate) of the residual material provided the title compound as a white solid (101 mg), m.p. 184-187 0
C.
Elemental Analysis: Calculated: C, 58.20; H, 5.46; N, 7.98 Found: C, 58.06; H, 5.60; N, 7.85 EXAMPLE 4 3 -(4-Methvlsulfonvl)phenvl-2-piperidin-1-vlDvridine Step 1: 2 -Chloro-3-(4-methvlthio)phenvlpyridine To a solution of 2 -chloro-3-hydroxypyridine (2 g) and triethylamine (5 mL) in CH2C12 (50 mL) at -78 0 C was added trifluoromethanesulfonic anhydride (2.8 mL) and was then warmed to Saturated ammonium chloride was added and the mixture was extracted with ether. The organics were washed with water and brine, dried and concentrated. The residual material containing the crude triflate, 4-methylthiobenzene boronic acid (Li, et. al. J. Med. Chem. 1995, 38, 4570) (2.6 2M aqueous sodium carbonate (17 mL) and catalytic palladium tetrakis(triphenylphosphine) in ethanol/benzene (40 mL, 1:1) 44 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 was heated at reflux for 3 h. The mixture was cooled to diluted with water and extracted with ether. The organics were concentrated and the residue was subjected to flash chromatography (85:15 hexane/ethyl acetate). The title compound was obtained as a solid (640 mg).
Step 2: 2 -Chloro- 3 -(4-methylsulfonvl)phenvlpyridine Following the procedures described in Example 1, Step 3, but substituting 2 -chloro-3-(4-methylthio)phenylpyridine from Step 1 for 2 -amino- 3 4 -methylthio)phenyl-5-trifluoromethylpyridine, the title compound was obtained as a white solid.
Step 3: 3-(4-Methvlsulfonv1)phenvl-2-piperidin- 1-vlpvri dine A mixture of piperidine (0.5 mL), potassium carbonate (100 mg) and 2 -chloro- 3 -(4-methylthio)phenylpyridine (150 mg) in DMSO mL) was stirred at 165°C until tic analysis indicated completion of the reaction (15 Water was added and the mixture was extracted with ether. The organics were washed with brine, dried (MgSO4) and concentrated. Flash chromatography (7:3 hexane/ethyl acetate) provided the title compound as a yellow solid (80 mg).
Elemental Analysis: Calculated: C, 64.53; H, 6.37; N, 8.85 Found: C, 64.71; H, 6.40; N, 8.47 EXAMPLE 3-(4-Methylsulfonvl)Dhenvl-2-(1.2.3.6-tetrahydropvridinvl)-5trifluoromethvlpyridine Following the procedures described in Example 1, Step but substituting 1, 2 3 ,6-tetrahydropyridine for pyrrolidine, the title compound was obtained as a solid, m.p. 149-149.5 0
C.
45 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/0086 1 EXAMPLE 6 2 -(Homoriperidin-1-vl)-3-(4-methvlsulfony)phenl.5.
trifl uorom ethyl pyrijdine Following the procedures described in Example 1, Step but substituting homopiperidine for pyrrolidine, the title compound was obtained as a solid, m.p. 161.4-163.5*C.
EXAMPLE 7 3 4 -Methvlsulfonv1)phenvl-2-((2S).2.hvdroXM ethv1)pvnoli din- triflu orom ethvlp3vridine Step 1: 2-Chl oro-3 ethyl sulfonvl)h env1 -5 -tritl u orom ethyl pRildine To a solution of 2 -amino-3-(4-methylsulfonyl)phenyls..
trifluoromethylpyridine (1.2 g) in water/concentrated HCl (9.5 mL:1 niL) at 0 0 C was added a solution of sodium nitrite (262 mag) in 5 niL water.
The mixture was warmed to r.t. and stirred overnight. An additional mag of sodium nitrite was added and after 3 h the heterogeneous mixture was filtered. A portion of the solid (250 mag) and POC13 (110 mL) in DMF (2 naL) was heated at 70'C for 60 h. The mixture was cooled to r.t., diluted with water and extracted with ethyl acetate. The organics were washed with brine, dried and concentrated to provide the title compound as a pale yellow solid (270 mg) that was used as such in the subsequent reaction.
Step 2: 3-(4-Methvlsulfonvl).phenvl2((2S).2.
hydroxvm ethyl )pvoli din- 1 -vi 5-trifluorom ethvlTuvri dine A mixture of 2 -pyrrolidinernethanol (400 nag), cesium carbonate (1 g) and 2 -chloro- 3 trifluoromethylpyridine (600 mag) in DMF (6 mL) was stirred at until tlc analysis indicated completion of the reaction (15 Water was added and the mixture was extracted with ether. The organics were washed with brine, dried (MgSO4) and concentrated. Flash 46 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/0086 1 chromatography (3:7 hexane/ethyl acetate) provided the title compound as a white foam (470 mg).
Elemental Analysis: Calculated: C, 53.99; H, 4.78; N, 7.00 Found: C, 54.13; H, 4.93; N, 6.89 EXAMPLE 8 3-(4-Methyl sulfonyl )nhenvl-2-((2R)-2-hvdrox= ethyD )prroli din- 1 -vi trifluorom ethyl nyridine Following the procedures described in Example 7, Step 2, but substituting (R)-2-pyrrolidinemethanol for pyrrolidinemethanol, the title compound was obtained as a white foam.
Elemental Analysis: Calculated: C, 53.99; H, 4.78; N, 7.00 Found: C, 53.75; H, 4.76; N, 6.78 EXAMPLE 9 5-Chloro-3-(4-m ethvlsulfonyl)2h envl2((M2-hydro2.m ethylbvrroli din- 1-vlpvridine A mixture of (S)-2-pyrrolidlinem ethanol (2 mL), GuI (16 mg) and 2 ,5-dlichloro-3-(4-methylsulfonyl)phenylpyricjjne (510 mg) was stirred at 100'C until tlc analysis indicated completion of the reaction Water was added and the mixture was extracted with ether. The organics were washed with brine, dried (MgSO4) and concentrated.
Flash chromatography (3:7 hexane/ethyl acetate) provided the title compound as a white foam (500 mg).
Elemental Analysis: Calculated: C, 55.66; H, 5.22; N, 7.64 Found: C, 55.68; H, 5.32; N, 7.47 EXAMPLE 3 4 -Methylsulfonyv)nhenyv2-((2S)-2..methoxym ethyl )Dvrrolidin- trifluorom ethylpvyri dine -47 SUBSTITUTE SHEET (RULE 26) 1, WO 99/14 195 PCT/CA98/0086 1 Following the procedures described in Example 7';Step 2, but substituting 2 -(methoxymethyl)pyrrolidine for pyrrolidinemethanol, the title compound was obtained as a white foam.
Elemental Analysis: Calculated: C, 55.06; H, 5.11; N, 6.76 Found: C, 55.24; H, 4.94; N, 6.69 EXAMPLE 11 3-4MtysloyIDey--(2)2aeg~ty)R oidn triflu orom ethyl Dyrjdine To a solution of 3 4 -methylsulfonyl)phenyl-2-((2S)-2hydroxymethyl)pyrrolidin- l-yl-5-trifluoromethylpyridine (200 mg) and DMAP (catalytic) in CH2CI2 (2 mL) at r.t. was added acetic anhydride (0.1 mL). After 2 h, water was added and the mixture was extracted with ether. The organics were dried and concentrated. Flash chromatography of the residual material (3:2 hexnae/ethyl acetate) provided the title compound as a white foam (160 mg).
Elemental Analysis: Calculated: C, 54.29; H, 4.78; N, 6.33 Found: C, 54.09; H, 4.74; N, 6.17 EXAMPLE 12 -Chl oro- 3-(4-m ethyl sul fonlDph enl S) 2-.meth owMethvl)pvrlolidin- 1-ylpyridine To a solution of 5-chloro-3-(4-methylsulfonyl)phenyl-2-((2S 2 -hydiroxymethyl)pyrrolidin-1-ylpyridine (65 mg) and methyl iodide (0.1 mL) in DMF (5 mL) at r-t. was added potassium t-butoxide (0.5 mL of a 1 M solution in THF). After 10 min, saturated ammonium chloride was added and the mixture extracted with ethyl acetate. The organics were dried and concentrated. Flash chromatog-raphy of the residue (4:1 hexane/ethyl acetate) provided the title compound as a white foam.
'H NMR (500 MHz, acetone-d 6 d 1.5-1.63 (in, 1H), 1.6-1.83 (in, 2H), 1.97- 2.05 (in, 1H), 2.60 (dt, 1H), 2.85 (dt, 1H), 3.15 3H), 3.30 3H), 3.40 (dd, 1H), 3.59 (dd, 1H), 4.48 (mn. 1H), 7.55 1H), 7.71 2H), 7.98 2H), 8.11 1H).
48 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 EX-AMPLE 13 3 4 -Methyisulfonyl)ph-enyb2-(2..hydroxc.methyI)pjpeijdin-1-vl-5trifl uorom ethylpvri dine A mixture of 2 -(hyd-roxymethyl)piperidine (1 mL), GuI mg) and 2 -chloro- 3 -(4-methylsulfonyl )phenyl-5-trifluorom ethylpyridine (200 mag) was stirred at 100 0 C for 15 h. Water was added and the mixture was extracted with ether. The organics were washed with brine, dried (MgSO4) and concentrated. Flash chromatography (1:1 hexane/ethyl acetate) provided the title compound as a white foam (50 mag).
Elemental Analysis: Calculated: C, 55.06; H, 5.11; N, 6.76 Found: C, 54.74; H, 5.34; N, 6.51 EXAMPLES 14 AND 4 -Methylsulfonvl)p2henyb2..(3..hydro1xrnethvl)piperJ din- 1-I trifluorom ethvIlpvri dine and (+)-3-4-Methvlsulfonvl )Dhenyl-2-(3hydroxvnaethyl)piperidin. 1 -yl- 5-triflu orom ethvlpvi dine Step 1: Racenaic 3-(4-Methvlsufonylnhenl.2-(3.
hydroxym ethvlDpi Deri din 1 5-trifl uorom ethyl pyri dine Following the procedures described in Example 13, but substituting 3 -(hydroxymethyl)piperi dine for 2- (hydroxymethyl)piperidine, the title compound was obtained as a white solid.
Elemental Analysis: Calculated: C, 5*5.06; H, 5.11; N, 6.76 Found: C, 54.74; H, 5.15; N, 6.62 Step 2: (-)-3-(4-Methylsulfonl)henl2.(3.
hvdroxvm ethvlDpijeri din- l-yl-5 -triflu orom ethylpvri dine and 3 4 -Methyvlsulfonvldpenvi..2 -(3-hydroxym ethyl)piperi din- 1 Y-1- A portion (100 nag) of the raceinic material obtained in Step 1 was subjected to HPLC using a chiral column (chiralpak AD from 49 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 DAICEL; 2 X 25 cm) and an eluant of hexane/isopropanol (80:20) at a flow rate of 9 mL/min (10 X 10 mg injections). The first compound to be eluted (monitoring at 290 nm) with a retention time of 11.6 min was obtained as a white solid (40 mg) after concentration -780; c 0.205, CH2C12). 1 H NMR analysis of the derived Mosher's ester indicated >98% ee. The second eluting compound (retention time 12.5 min) was obtained as a white solid (15 mg) after concentration +72.20; c 0.18, CH2C12). 1H NMR analysis of the derived Mosher's ester indicated -98% ee.
EXAMPLE 16 5-Chloro-3-(4-methylsulfonvl )phenvl-2-(3-hvdroxvmethvl)piperidin- 1vlpvridine Following the procedures described in Example 9, but substituting 3-(hydroxymethyl)piperidine for (S)-2-pyrrolidinemethanol, the title compound was obtained as a pale yellow foam.
Elemental Analysis: Calculated: C, 56.76; H, 5.56; N, 7.35 Found: C, 52.92; H, 5.75; N, 7.34 EXAMPLE 17 3 4 -Methvlsulfonvl)nhenvl-2-(3-hvdroxvmethvl-3-methyl)piperidin- 1-v- 5 -trifluoromethylpvridine Step 1: 3-Hydroxymethyl-3-methylpiperidine To ethyl nipecotate (1.3 g) in THF (20 mL) at r.t was added potassium bis(trimethylsilyl)amide (18 mL of a 0.5 M solution in toluene). After 1 h, methyl iodide (0.5 mL) was added and the mixture was stirred for 15 h. Water was added and the mixture extracted with ether. The organics were washed with brine, dried and concentrated.
The residual material (1.3 g) was dissolved in THF (20 mL) and treated with lithium aluminum hydride (8.7 mL of a 1 M solution in THF) at r.t.
After 15 h, the mixture was cooled to -5 0 C and aqueous sodium 50 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 potassium tartrate was added followed by concentrated NH40H, 10 N NaOH and the resulting mixture was stirred for 30 min. The mixture was filtered through anhydrous sodium sulfate and the filtrate was concentrated from toluene twice. The residual oil (1 containing the title compound, was used without further purification in Step 2.
Step 2: 3-(4-Methylsulfonvl)Dh envl-2-(3-hvdroxymethyl.3- A mixture of crude 3 -hydroxymethyl-3-methylpiperidine from Step 1 (500 mg) and 2 -chloro-3-(4-methylsulfonyl)phenyl-5trifluoromethylpyridine (330 mg) was stirred at 100°C for 3 h. Water was added and the mixture was extracted with ethyl acetate. The organics were washed with brine, dried (MgS04) and concentrated. Flash chromatography (2:3 hexane/ethyl acetate), followed by stirring the semi-purified material vigorously in ether/hexane, provided the title compound as a white solid (250 mg).
Elemental Analysis: Calculated: C, 56.06; H, 5.41; N, 6.54 Found: C, 55.83; H, 4.70; N, 6.42 EXAMPLE 18 3-( 4 -Methvlsulfonvl)phenvl-2-(3-hvdroxvmethvl)homopiperidin-1-vl-5triflu oromethylpvridine Step 1: N-Benzvl e-caprolactam To a solution of e-caprolactam (28.3 g) in THF (500 mL) and DMF (20 mL) at r.t. was added sodium hydride (12 g of 60% in oil) portionwise. After the addition was complete, benzyl bromide (29.7 mL) was added dropwise and upon completion, the mixture was stirred for h. To the mixture was carefully added saturated ammonium chloride and the resulting mixture was extracted twice with ethyl acetate. The organics were washed with water and brine, dried and concentrated.
The title compound was obtained as a white solid and used in Step 2 without further purification.
51 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 Step 2: 3-(Hydroxvmethvl)homopiperidine To a solution of LDA (prepared at 0°C from 5.3 mL of diisopropylamine and 15.8 mL of 2.4 M n-BuLi in hexanes) in THF (150 mL) at -78°C was added N-benzyl e-caprolactam (7 g) from Step 1. The mixture was warmed to -40 0 C and then cooled to -98 0 C. To the cold solution was added ethyl formate (5 eq) and then the mixture was warmed to r.t. Saturated ammonium chloride was added and the resulting mixture was extracted twice with ethyl acetate. The organics were washed with water and brine, and then filtered through a pad of silica gel. The filtrate was concentrated to provide the formylated product (6 g) that was used as such. The residual material was dissolved in THF (100 mL) and treated with lithium aluminum hydride (2 eq of 1 M solution in THF) at r.t. After 15 h, the mixture was cooled to 5 0 C and aqueous sodium potassium tartrate was added followed by concentrated NH40H, 10 N NaOH and the resulting mixture was stirred for 30 min. The mixture was filtered through anhydrous sodium sulfate and the filtrate was then filtered through a pad of silica gel. The filtrate was concentrated to provide the reduced product (2.2 g) that was used as such. A mixture of the crude material and 10% Pd-C (200 mg) in ethanol (100 mL) was stirred under an atmosphere of hydrogen (1 atm) for 2 days. The mixture was filtered through a pad of Celite and the filtrate was concentrated. Flash chromatography of the residual material (ethyl acetate) provided the title compound as .an oil that was used as such in Step 3.
Step 3: 3-(4-Methvlsulfonvl)phenvl-2-(3hvdroxvmethyl)hom opiperidin- trifluorom ethylpyridine Following the procedures described in Example 13, but substituting 3 -(hydroxymethyl)homopiperidine for 2- (hydroxymethyl)piperidine, the title compound was obtained as a white solid.
Elemental Analysis: Calculated: C, 56.06; H, 5.41; N, 6.54 Found: C, 55.86; H, 5.30; N, 6.44 52 SUBSTITUTE SHEET (RULE 26) 0.
WO 99/14195 PCT/CA9810086 i EXAMPLE 19 3 4 -Methvlsulfony1),Dhenl-2-(2-(2hdroethv))piDeriinvlS trifluorom ethljpvridine A mixture of 2-piperidineethanol (1.5 GuI (20 mg) and 2chloro- 3 -(4methylsulfonyl)phenyl.5.trifluoromethylpyidine (336 mg) was stirred at 130C for 15 h. Water was added and the mixture was extracted with ether. The organics were washed with brine, dried (MgSO4) and concentrated. Flash chromatography (1:1 hexane/ethyl acetate) provided the title compound as a white solid (56 mg), m.p. 136- 137 0
C.
EXAMPLES 20 AND 22 3 4 -Methvlsulfonvl)Dhenyl-2(4oxo)niDeri din- trifluoromethvlDvrjdine and 3-(4-Methlsulfonvl)nhenl-2-(4hvdroxv)piDeridin- 1 Step 1: 3-(4-Methvlsulfonvl )phenl-2-(4-hdrov)piperi din- trifluoromethylDridine A mixture of 4-hydroxypiperidine (1 GuI (20 mg), diisopropylethylamine (1 mL) and 2 -chloro-3-(4-methylsulfonyl)phenyl-5trifluoromethylpyridine (336 mg) was stirred at 100C for 15 h. 1 N HCl and CH2CI2 were added and the mixture was extracted with ethyl acetate and ether. The combined organics were washed with saturated ammonia and brine, dried (MgSO4) and concentrated. Flash chromatography (1:1 hexane/ethyl acetate) provided the title compound (Example 22) as a white solid (147 mg), m.p. 185-186.5*C.
Step 2: 3 4 -Methvlsulfonvl)henvl.-2-(4-oxo)Tpeiidin. trifluoromethvlDidine A mixture of 3-(4-methylsulfonyl)phenyl-2-(4hydroxy)piperidin-1-yl-5 -trifluoromethylpyricdjne from Step 1 (400 mg), 53 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 3A' molecular sieves (1 TPA-P (catalytic) and NMO (234 mg') in acetonitrile (10 mL) was stirred for 15 h at r.t. The mixture was filtered and the filtrate was concentrated. Flash chromatography (1:1 hexane/ethyl acetate), followed by stirring the semi-purified material vigorously in ether, provided the title compound (Example 20) as a beige solid (77 mg).
Elemental Analysis: Calculated: C, 54.27; H, 4.30; N, 7.03 Found: C, 53.98; H, 4.23; N, 6.91 EXAMPLES 21 AND 23 3 4 -Methyl sulfonylDhenyl -20-3oxo)iperi din trifluoroinethylpvrjdine and3-(4-Methylsulfonvl)phenyl-2(3hvdroxv)pip~eri din- 1l-vl- 5-trifl uoromethlpyvridine Step 1: 3 4 -Methvlsulfonvl)pheiil-2-(3-hydro~)TDjneri din- 1 -yl trifi uoromethylpvri dine Following the procedures described in Examples 20 and 22, Step 1, but substituting 3-hydroxypiperi dine for 4-hydiroxypiperi dine, the title compound (Example 23) was obtained as a white solid.
Elemental Analysis: Calculated: C, 53.99; H, 4.78; N, 7.00 Found: C, 53.72; H, 5.00; N, 7.10 Step 2: 3-(4-Methvl1sulfonv~phenyii-24(3-oxo)piperi din- trifluorom-ethylpvri dine Following the procedures described in Examples 20 and 22, Step 2, but substituting 3 4 -methylsulfonyl)phenyl-2-(3hyioyppzdn1y--rfurmtyprdn from Step 1 for 3-(4methylsulfonyl)phenyl-2-(4-hydoxy)piperidin1yl.5 trifluoromethylpyridline, the title compound (Example 21) was obtained as a beige solid, m.p. 176-176.50C.
EXAMPLE 24 -54 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCTICA98/0086 1 2-(4 .4-Difluorohpineri din- 1-yl--(4-methvlsulfonvl~phenvbs..
triflu orom ethyl D~nridine A mixture of 3 4 -methylsulfonyl)phenyl-2-(4-oxo)piperidin.
l-yl-5-trifluoromethylpyridine (480 mg) and DAST (0.32 rnL) in benzene (12 mL) was heated at reflux for 3 h. Saturated sodium carbonate was carefully added and the mixture was extracted with ethyl acetate. The combined organics were washed with brine, dried (MgSO4) and concentrated. Flash chromatography (3:2 hexane/ethyl acetate), followed by stirring the semi-purified material vigorously in ether, provided the title compound as a white solid (340 mg).
Elemental Analysis: Calculated: C, 51.43; H, 4.08; N, 6.66 Found: C, 51.62; H, 3.88; N, 6.57 EXAMPLE 2(3 .3-Diflu oro)piperi din- 1-yl 3 -(4-methylsulfonl)ph env trifl uorom ethylnyr:i dine Following the procedures described in Examples 24, but substituting 3 4 4 -m ethylsulfonyl)phenyl2.43 -oxo)pip eri dn- 1 -yl-5 trifluoromethylpyridine for 3 4 -methylsulfonyl)phenyl-2(4.
oxo)piperidin- 1 yl- 5-trifl uoromethylpyri dine, the title compound was obtained as an off-white solid, m.p. 152.5-153.5*C.
EXAMPLE 26 2 4 -Fluoro)p-eridin-l.vl-3-(4-metbylsulfonyI)phenyl-5 trifluorom ethylr~vri dine To a solution of 3 4 -methylsulfonyl)phenyl-2-(4- (150 mg) in CH2CI2 (1.9 mL) at -78'C was added DAST (74 mL). The mixture was warmed to r.t.
and then saturated sodium carbonate was carefully added. The mixture was extracted with ethyl acetate and the combined organics were washed with brine, dried (MgSO 4 and concentrated. Flash 55 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 chromatography (3:2 hexane/ethyl acetate), followed by stirring the semi-purified material vigorously in ether, provided the title compound as a white solid (115 mg), m.p. 136-137.5°C.
EXAMPLE 27 3-( 4 -Methlsulfonyl)phenvl-2-morpholin-4-vl-5-trifluoromethvlpvridine Following the procedures described in Example 13, but substituting morpholine for 2-(hydroxymethyl)piperidine, the title compound was obtained as a white solid, m.p. 159-160 0
C.
EXAMPLE 28 3 -(4-Methvlsulfonvl)phenvl-2-thiomorpholin4-v-5 trifluoromethylpvridine A mixture of thiomorpholine (350 mg), CuI mg), N-ethyl morpholine (2 mL) and 2-chloro-3-(4- (500 mg) was stirred at 128 0 C for 15 h. 1 N HC1 and CH2C12 were added and the mixture was extracted with ethyl acetate and ether.. The combined organics were washed with saturated ammonia and brine, dried (MgSO4) and concentrated. Flash chromatography (1:1 hexane/ethyl acetate), followed by stirring the semi-purified material vigorously in ether, provided the title compound as a white solid (460 mg).
Elemental Analysis: Calculated: C, 50.74; H, 4.26; N, 6.96 Found: C, 50.56; H, 4.34; N, 6.90 56 SUBSTITUTE SHEET (RULE 26)

Claims (2)

1. A compound of Formula I S02R' R 2 N AR I or a pharmaceutically acceptable salt thereof wherein: -AR is selected from the group consisting of N-] (a) N X (d) N (b) x (e) xI (c) (f) N X( (i) (i) N N (h) X is selected from the group consisting of CR 3 R 4 57 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/0086 1 (b)O0, S) R 1 is selected from the group consisting of CH3, NT2, NTHC(O)CF3, R 2 is chosen from the group consisting of hydrogen C1-6alkyl C1-6alkoxy, Cl-6alkylthio, C1-6fluoroalkyl, Mf Cl-Gfluoroalkoxy, CN, -C02R 6 t Wi -O(R 7 )(R 8 )-OH, Wj -C1-6alkl-C02-R 9 (k halo, hydroxy, (in) N3, (mn) N02, N-Rl 0 R 1 1 NHC OR 1 2 R 3 and R 4 are independently chosen from the group consisting of hydrogen, Cl-6alkyl, (CH2)pOR 5 F) or R 3 and R 4 are together 0, R 5 is selected from the group consisting of hydrogen, C1-GalikYl, R 6 to R 12 are independently chosen from the group consisting of hydrogen C1...alkyl, and p is 0, 1, 2.
58- SUBSTITUTE SHEET (RULE 26) 59 2. A compound according to claim 1 wherein R' is CH 3 3. A compound according to claim 1 wherein R 2 is halo or CI-6fluoroalkcyl. 4. A compound according to claim 1 wherein X is CR 3 R 4 A compound according to claim I wherein R 2 is chosen from the group consisting of hydrogen, C 1 6 allcyl, CI-6alkoxy, C 1 6 fluoroalkyl, CN, halo, hydroxy. 6. A compound according to claim 1 wherein AR is selected from N N 15X30 (c) S S. N N C (N) (g) (e) 7. A compound according to claim 1 wherein [K-\LIBAA]09]73.doc:sak WO 99/14195 PCT/CA98/00861 -AR is selected from the group consisting of (c) N X N X--X (e) (9) X is selected from the group consisting of CR 3 R 4 R 1 is selected from the group consisting of CH3, NH2, R 2 is chosen from the group consisting of hydrogen C1-4alkyl C1-4alkoxy, C1-4alkylthio, C1-4fluoroalkyl, CN, halo, hydroxy, R 3 and R 4 are independently chosen from the group consisting of hydrogen, Ci-4alkyl, (CH2)pOR 5 F, or R 3 and R 4 are together O, R 5 is selected from the group consisting of 60 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 hydrogen, C1-6alkyl, p is 0, 1, 2. 8. -AR is selected A compound according to Claim 7 wherein from the group consisting of (b) (b) (c) (d) (d) (e) (e) N (x) (g) X is selected from the group consisting of CR 3 R 4 R1 is selected from the group consisting of CH3, NH2, R 2 is C1-4fluoroalkyl, R 3 and R 4 are independently chosen from the group consisting of hydrogen, C1-3alkyl, (CH2)pOR 5 F, or R 3 and R 4 are together O, R 5 is selected from the group consisting of hydrogen, methyl or ethyl, p is 0 or 1. 61 SUBSTITUTE SHEET (RULE 26) WO 99/14195 PCT/CA98/00861 9. A compound selected from the group consisting of 3-(4-Methylsulfony1)phenyl-2-pyrrolidin- l-yl- 5 trifluoromethylpyridine, 3 -(4-Methylsulfonyl)phenyl-2-piperidin.. trifluorom ethylpyri dine, 5-Chloro-3-(4-methylsulfonyl)phenyl.2-pipei din- 1- ylpyridine, 3 -(4-Methylsulfonyl)phenyl.2-piperidin-1 -ylpyridine, 3-(4-Methylsulfonyl)phenyl-2-( 1,2,3 ,6-tetrahydropyridin- 1- 2-(Homopiperidin- l-yl)-3-(4-methylsulfonyl)phenyl-5- trifluoromethylpyri dine, 3-(4-Methylsulfonyl)phenyl-2-(( 2S)-2- hydroxymethyl )py-roli din- 1l-yl- 5 -trifluorom ethyl pyri dine, 3-(4-Methylsulfonyl)phenyl-2-((2R)-2- hydroxymethyl)pyrrolidin- 5-Chloro-3-(4-methylsulfonyl)phenyl-2-((2S)-2 hydroxymethyl)pyrrolidin- l-ylpyri dine, 3-(4-Methylsulfonyl)phenyl-2-((2S)-2- (11) 3-(4-Methylsulfonyl)phenyl-2-((2S acetoxym ethyl)pyrroli din- 1 -yl-5-trifluorom ethylpyri dine, (12) 5-Chloro-3-(4-methylsulfonyl)phenyl-2-((2S)-2- methoxymethyl)pyrrolidin- l-ylpyridiine, (13) 3 4 -Methylsulfonyl)phenyl-2-(2-hydroxymethyl)pipe-idin.. 1 (14) (-)-3-(4-Methylsulfonyl)phenyl-2-(3- hydiroxymethyl )piperidin- (+)-3-(4-Methylsulfonyl)phenyl-2-(3- hydroxymethyl)piperidin- l-yl-5-trifluoromethylpyri dine, (16) 5-Chloro-3-(4-methylsulfonyl)phenyl-2-(3. hydroxymethyl)piperidin- 1-ylpyridine, (17) 3-(4-Methylsulfonyl)phenyl-2-( 3-hydroxymethyl-3- methyl)piperidin- 62 SUBSTITUTE SHEET (RULE 26) 63 (18) 3-(4-Methylsulfonyl)phenyl-2-(3-hydroxymethyl)homopiperidin- trifluoromethylpyridine, (19) 3-(4-Methylsulfonyl)phenyl-2-(2-(2-hydroxyethyl))piperidin- trifluoromethylpyridine, (20) 3-(4-Methylsulfonyl)phenyl-2-(4-oxo)piperidin-1-yl-5-trifluoromethylpyridine, (21) 3-(4-Methylsulfonyl)phenyl-2-(3 -oxo)piperidin- 1 (22) 3-(4-Methylsulfonyl)phenyl-2-(4-hydroxy)piperidin-1-yl-5-trifluoromethylpyridine, (23) 3-(4-Methylsulfonyl)phenyl-2-(3-hydroxy)piperidin-1-yl-5-trifluoromethylpyridine, (24) 2-(4,4-Difluoro)piperidin-1-yl-3-(4-methylsulfonyl)phenyl-5- trifluoromethylpyridine, 2-(3,3-Difluoro)piperidin-1l-yl-3-(4-methylsulfonyl)phenyl-5- trifluoromethylpyridine, (26) 2-(4-Fluoro)piperidin- 1 -yl-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine, (27) 3-(4-Methylsulfonyl)phenyl-2-morpholin-4-yl-5-trifluoromethylpyridine, s15 (28) 3-(4-Methylsulfonyl)phenyl-2-thiomorpholin-4-yl-5-trifluoromethylpyridine. 10. A compound which is a title compound of any one of the Examples. 11. A process of producing a compound according to claim 10, the process being substantially as hereinbefore dsecribed with reference to any one of the Examples. 12. A pharmaceutical composition comprising: a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier. 13. An anti-inflammatory pharmaceutical composition comprising an effective anti-inflammatory amount of a compound according to claim 9, in association with a pharmaceutically acceptable carrier. 14. A COX-2 selective, relative to COX-1, inhibitor pharmaceutical composition comprising an effective COX-2 selective inhibiting amount of a compound according to claim 9 in association with a pharmaceutically acceptable carrier. A method of treating an inflammatory disease susceptible to treatment with non-steroidal anti-inflammatory agent in a patient, the method comprising: administration to the patient of a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier. 16. A method of treating an inflammatory disease susceptible to treatment with non-steroidal anti-inflammatory agent in a patient, the method comprising: administration to the patient of a non-toxic therapeutically effective amount of a compound according to [I:\DAYLIB\ibaa]09173.doc:sak 64 a compound according to any one of claims 1 to 10 or of a composition according to claim 12. 17. A compound according to any one of claims 1 to 10 or a composition according to claim 12 when used for treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent. 18. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent. 19. A method of treating a cyclooxygenase mediated disease advantageously to treated by an active agent that selectively inhibits COX-2 in preference to COX-1 in a patient, the method comprising: administration to the patient of a non-toxic therapeutically effective amount of a compound according to claim 1. 20. A method of treating a cyclooxygenase mediated disease advantageously 0* treated by an active agent that selectively inhibits COX-2 in preference to COX-1 in a 0 15 patient, the method comprising: administration to the patient of a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 10 or of a composition according to claim 12. 21. A compound according to any one of claims 1 to 10 or a composition according to claim 12 when used for treating a cyclooxygenase mediated disease 20 advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1. "1 22. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for treating a cyclooxygenase mediated disease advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1. Dated 10 October, 2001 Merck Frosst Canada Co. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [I:\DAYLIB\ibaa]09173.doc:sak
AU90586/98A 1997-09-12 1998-09-11 2-aminopyridines as inhibitors of cyclooxygenase-2 Ceased AU741754B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5870697P 1997-09-12 1997-09-12
US60/058706 1997-09-12
GB9800689 1998-01-14
GBGB9800689.3A GB9800689D0 (en) 1998-01-14 1998-01-14 2-aminopyridines as inhibitors of cyclooxygenase-2
PCT/CA1998/000861 WO1999014195A1 (en) 1997-09-12 1998-09-11 2-aminopyridines as inhibitors of cyclooxygenase-2

Publications (2)

Publication Number Publication Date
AU9058698A AU9058698A (en) 1999-04-05
AU741754B2 true AU741754B2 (en) 2001-12-06

Family

ID=26312938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90586/98A Ceased AU741754B2 (en) 1997-09-12 1998-09-11 2-aminopyridines as inhibitors of cyclooxygenase-2

Country Status (8)

Country Link
EP (1) EP1015431B1 (en)
JP (1) JP4368524B2 (en)
AT (1) ATE293602T1 (en)
AU (1) AU741754B2 (en)
CA (1) CA2301590C (en)
DE (1) DE69829861T2 (en)
ES (1) ES2239402T3 (en)
WO (1) WO1999014195A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006312A (en) 1999-12-23 2004-06-21 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase2 inhibitors, compositions and methods of use.
WO2002006271A1 (en) * 2000-07-19 2002-01-24 F. Hoffmann-La Roche Ag Pyrimidine derivatives
HUP0302068A3 (en) 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
EP1406609B1 (en) 2000-12-21 2006-09-06 Nitromed, Inc. Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
PL1534305T3 (en) 2003-05-07 2007-03-30 Osteologix As Treating cartilage / bone conditions with water-soluble strontium salts
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757073A (en) * 1986-09-30 1988-07-12 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use
EP0591030A3 (en) * 1992-09-25 1994-04-27 Sanofi 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0647639A1 (en) * 1993-10-11 1995-04-12 Sanofi Heteroarylpiperidines, process for their preparation and pharmaceutical compositions containing them
DE4419247A1 (en) * 1994-06-01 1995-12-07 Merckle Gmbh New pyrrolizine keto-acid, keto-ester and carboxamide derivs.

Also Published As

Publication number Publication date
ES2239402T3 (en) 2005-09-16
CA2301590C (en) 2007-05-01
DE69829861T2 (en) 2006-03-02
JP4368524B2 (en) 2009-11-18
JP2001516743A (en) 2001-10-02
CA2301590A1 (en) 1999-03-25
DE69829861D1 (en) 2005-05-25
AU9058698A (en) 1999-04-05
ATE293602T1 (en) 2005-05-15
EP1015431B1 (en) 2005-04-20
EP1015431A1 (en) 2000-07-05
WO1999014195A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
EP0912518B1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6812346B2 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5922742A (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
AU741755B2 (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6046217A (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
AU738727B2 (en) Pyridazinones as inhibitors of cyclooxygenase-2
AU741754B2 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
US6004950A (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
AU6818298A (en) Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
CA2252401C (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)